{
  "symbol": "AMGN",
  "year": 2023,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1672,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.146
  },
  "top_positive": [
    {
      "sent": "26 Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended September 30, 2023 Nine months ended September 30, 2023 Product sales Other income (expense), net Interest expense, net Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 6,548 $ 685 $ ( 759 ) $ 19,077 $ 2,431 $ ( 2,054 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 33 $ \u2014 $ \u2014 $ 121 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 86 ) $ \u2014 $ \u2014 $ ( 57 ) $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 58 $ \u2014 $ \u2014 $ 63 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 37 ) $ \u2014 $ \u2014 $ 5 Three months ended September 30, 2022 Nine months ended September 30, 2022 Product sales Other income (expense), net Interest expense, net Product sales Other income (expense), net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 6,237 $ 100 $ ( 368 ) $ 18,249 $ ( 747 ) $ ( 991 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 69 $ \u2014 $ \u2014 $ 149 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 198 ) $ \u2014 $ \u2014 $ ( 461 ) $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 240 $ \u2014 $ \u2014 $ 734 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 220 ) $ \u2014 $ \u2014 $ ( 670 ) __________ (1) Gains on hedged items do not exactly off\nof our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash provided by (used in) financing activities.",
      "score": 0.9913
    },
    {
      "sent": "In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) consolidated interest expense, each as defined and described in the credit agreement.",
      "score": 0.9686
    },
    {
      "sent": "In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) consolidated interest expense, each as defined and described in the credit agreement.",
      "score": 0.9686
    }
  ],
  "top_negative": [
    {
      "sent": "In Amgen\u2019s lawsuit for patent infringement damages against Sanofi K.K., on September 27, 2023, the Tokyo District Court found Amgen\u2019s patent claims invalid and dismissed Amgen\u2019s lawsuit for damages.",
      "score": -0.8934
    },
    {
      "sent": "The following tables summarize recorded charges related to the restructuring plan by type of activity and the locations recognized within the Condensed Consolidated Statements of Income (in millions): Three months ended September 30, 2023 Separation costs Asset impairments and other charges Total Cost of sales $ \u2014 $ 1 $ 1 Research and development \u2014 \u2014 \u2014 Selling, general and administrative \u2014 13 13 Other 16 1 17 Total $ 16 $ 15 $ 31 Nine months ended September 30, 2023 Separation costs Asset impairments and other charges Total Cost of sales $ \u2014 $ 36 $ 36 Research and development \u2014 17 17 Selling, general and administrative \u2014 13 13 Other 182 4 186 Total $ 182 $ 70 $ 252 As of September 30, 2023, total restructuring liability decreased to $ 54 million primarily due to payments related to separation costs.",
      "score": -0.872
    },
    {
      "sent": "Pressures to decrease drug expenditures may further intensify as the COVID-19 pandemic has strained government budgets and as economic conditions continue to worsen in certain regions, including in Europe where high inflation and the energy crisis relating to the Russia\u2013Ukraine conflict are challenging the economies in that region.",
      "score": -0.872
    }
  ],
  "forward_snippets": [
    "We now expect that we will incur $ 250 million to $ 350 million of pretax charges in 2023 in connection with our restructuring plan, including (i) separation and other headcount-related costs with respect to staff reductions and (ii) asset-related charges that consist primarily of asset impairments and other related costs resulting from rationalization of our geographic footprint.",
    "We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.",
    "We believe the fair value option best reflects the economics of the underlying transaction.",
    "The remaining contingent consideration liability as of September 30, 2023, primarily relates to potential development and regulatory milestones for R&D programs acquired via the Teneobio acquisition that we continue to pursue.",
    "We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; and in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2022; and in Note 14, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2023 and June 30, 2023."
  ]
}